As the scientific community continues to explore telomere biology and peptide therapeutics, Epithalon stands out as a beacon of whats possible in regenerative medicine
Clinical trials have demonstrated a 65 percent reduction in vertebral fracture risk and a 35 to 53 percent reduction in non-vertebral fracture risk after 20 months of treatment at 20 micrograms per day
Systematic reviews of BPC-157 in musculoskeletal applications identified 36 studies demonstrating improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injuries in preclinical models
Routes: intravenous (IV), intramuscular (IM) Administration frequency: weekly to biweekly Duration: short-term cycles or maintenance protocols Infusion rate must be controlled to minimize adverse reactions
Ethical approval This study has been ethically approved, IR.TBZMED.VCR.REC.1403.076